Clinical trial
An Open-label, Randomized Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema
NCT02316353 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Randomized Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema
- Lead sponsor
- CSL Behring
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2014
- Completion date
- September 21, 2017
- Enrollment
- 126 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.